Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
  • Patent number: 8962825
    Abstract: Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent —N? or —C?; B is a divalent radical selected from (B1), (B2), (B3), (B4), (B5) and (B6). wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical; and R is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— or (b) a radical of formula R-L1-Y1—(CH2)z—.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: February 24, 2015
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: David Charles Festus Moffat, Sanjay Ratilal Patel, Francesca Ann Day, Andrew James Belfield, Alistair David Graham Donald, Alan Hornsby Davidson, Alan Hastings Drummond
  • Patent number: 8937071
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 20, 2015
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Hilary Schenck Eidam, Kaushik Raha, Zhen Gong, Huiping Amy Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui Cheung
  • Publication number: 20140286935
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicant: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Paul HAMBLIN, Alan Lewis, Thomas Matthew Webb
  • Patent number: 8841463
    Abstract: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: September 23, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Christopher E Neipp, Michael R. Palovich
  • Publication number: 20140275111
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Hilary Schenck EIDAM, Kaushik Raha, Zhen Gong, Huiping Guan, Chengde Wu, Haiying Yang, Haiyu Yu, Zhiliu Zhang, Mui CHEUNG
  • Publication number: 20140256949
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, R4 and R5 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 11, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Linda N. CASILLAS, Adam Kenneth Charnley, Pamela A. Haile, Terry Vincent Hughes, Robert W. Marquis, JR., John F. Mehlmann, Michael Reilly, Joseph J. Romano, Robert R. Singhaus, JR.
  • Publication number: 20140256721
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: April 14, 2014
    Publication date: September 11, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Publication number: 20140213599
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
    Type: Application
    Filed: January 23, 2014
    Publication date: July 31, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Zehong WAN, Yingxia Sang, Qing Zhang
  • Publication number: 20140193517
    Abstract: Methods are provided for selecting a new therapeutic indication for at least one first pharmaceutical comprising the steps of: generating a drug-side effect (SE) association for said at least one first pharmaceutical; generating a disease-side effect (SE) association for at least one disease or disorder and at least one second pharmaceutical intended for treatment of said at least one disease or disorder; determining an association strength between the drug-side effect (SE) association and the disease-side effect (SE) association; selecting said at least one disease or disorder as a new therapeutic indication for said at least one first pharmaceutical if said at least one first pharmaceutical induces at least one side effect which is the same as at least one side effect induced by at least one second pharmaceutical intended for treatment of said at least one disease or disorder.
    Type: Application
    Filed: August 17, 2012
    Publication date: July 10, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Pankaj Agarwal, Lun Yang
  • Patent number: 8765743
    Abstract: The invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: July 1, 2014
    Assignee: Glaxosmithkline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Patent number: 8735390
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: May 27, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Publication number: 20140080830
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): And salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Patent number: 8658635
    Abstract: The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: February 25, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Ian Robert Baldwin, Kenneth David Down, Paul Faulder, Simon Gaines, Julie Nicole Hamblin, Joelle Le, Christopher James Lunniss, Nigel James Parr, Timothy John Ritchie, John Edward Robinson, Juliet Kay Simpson, Christian Alan Paul Smethurst
  • Patent number: 8656911
    Abstract: There is provided an actuation counter comprising a driver feature having one or more driver elements, which driver feature is arranged for drivable movement in response to an actuation; and a count member including one or more drive receipt elements arranged thereon for receipt of drive from said one or more driver elements of the driver feature for drivable movement of the count member. The driver feature includes one or more brake elements arranged to selectively interact with the count member to prevent overrun thereof when registering a count of an actuation. The actuation is suitably arranged for use with a drug dispenser device.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: February 25, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: David Vincent Elliman
  • Patent number: 8609657
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: December 17, 2013
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr
  • Publication number: 20130317037
    Abstract: The present invention provides a method of treating a human with cancer comprising detecting at least one mutation in a PIK3CA gene or at least one mutant protein encoded by said PIK3CA gene from at least one first sample from said human and administering to said human an effective amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide or a pharmaceutically acceptable salt thereof in a pharmaceutical composition if said at least one sample has at least one mutant PI3K protein or a mutation in the PIK3CA gene.
    Type: Application
    Filed: November 16, 2011
    Publication date: November 28, 2013
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Kurtis Earl Bachman, Joel David Greshock
  • Patent number: 8590529
    Abstract: An actuator for an inhaler for delivering medicament by inhalation, comprising: a housing for receiving a canister which comprises a body which includes a base and a head and defines a chamber containing medicament, and a valve stem which extends from the body and from which medicament is in use delivered on actuation of the canister; an outlet through which a user in use inhales; and a nozzle assembly which provides for delivery of medicament through the outlet, wherein the nozzle assembly comprises a nozzle block which receives the valve stem of the canister and, as a separately-formed component, a nozzle outlet which is fluidly connected to the nozzle block and includes an outlet orifice from which medicament is in use delivered.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: November 26, 2013
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Gregor John McLennan Anderson, Penelope Ann Burgess, Gary Thomas Crosby, Tristan Fairbrother, Philip William Farr
  • Patent number: 8586583
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): And salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: November 19, 2013
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr
  • Patent number: 8586590
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: November 19, 2013
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr
  • Patent number: 8575162
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: November 5, 2013
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr